Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 317 Years to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.

X
Trial Profile

Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 317 Years to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Abbott Biologicals BV
  • Most Recent Events

    • 15 Sep 2017 Status changed from recruiting to completed.
    • 31 Jul 2017 This trial has been completed in Finland (on-2017-04-14) according to European Clinical Trials Database record.
    • 06 Jul 2017 Trial has been completed inLithuania (end Date: 2017-04-14).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top